Populations underrepresented in clinical trials face worse health outcomes that will cost the United States trillions of dollars over the next three decades, according to a new report from the National Academies of Science, Engineering and Medicine.

The committee relied on economic projections developed using the USC Schaeffer Center’s Future Elderly Model (FEM), an economic microsimulation model that was used to calculate the burden from lost life, increased disability and lost productivity arising from disparities in diabetes, heart disease and hypertension.

To continue reading this story, click here.